Overview
BCAX market data
Price History
BCAX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.52 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.87 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.67 – $30.99 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.8B · P/B 2.30.
Company News
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20Benzinga · Aug 12, 2026, 6:23 PM
Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33Benzinga · Aug 12, 2026, 4:02 PM
Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39Benzinga · Aug 12, 2026, 3:46 PM
Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20Benzinga · Aug 12, 2026, 1:17 PM
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 ResultsBenzinga · Aug 12, 2026, 12:34 PM
Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $23Benzinga · Aug 12, 2026, 12:22 PM
BTIG Maintains Buy on Bicara Therapeutics, Raises Price Target to $39Benzinga · Aug 12, 2026, 9:37 AM
Bicara Therapeutics shares are trading lower after the company reported a wider net loss for the second quarter reflecting rising expenses.Benzinga · Aug 11, 2026, 5:06 PM
8-K filing — Bicara Therapeutics Inc. (BCAX)SEC EDGAR · Aug 11, 2026, 11:36 AM
Bicara Therapeutics Q2 EPS $(0.82) Beats $(0.84) EstimateBenzinga · Aug 11, 2026, 11:30 AM